It was shown that only one genetic aberration, the BCR-ABL translocation, is central to the pathogenesis of chronic myeloid leukaemia, which led to the development and subsequent approval of imatinib, a BCR-ABL kinase inhibitor for treating this cancer type [8]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.